CY1126099T1 - Φαρμακευτικη συνθεση που περιεχει κρυσταλλικη τοσυλικη σοραφενιμπη - Google Patents

Φαρμακευτικη συνθεση που περιεχει κρυσταλλικη τοσυλικη σοραφενιμπη

Info

Publication number
CY1126099T1
CY1126099T1 CY20231100340T CY231100340T CY1126099T1 CY 1126099 T1 CY1126099 T1 CY 1126099T1 CY 20231100340 T CY20231100340 T CY 20231100340T CY 231100340 T CY231100340 T CY 231100340T CY 1126099 T1 CY1126099 T1 CY 1126099T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical composition
composition containing
sorafenib tosylate
containing crystalline
crystalline sorafenib
Prior art date
Application number
CY20231100340T
Other languages
English (en)
Inventor
Stefan SCHELER
Heiko DEGENDORFER
Johannes Raneburger
Franz Schwarz
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of CY1126099T1 publication Critical patent/CY1126099T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται μια στερεά δοσολογική μορφή από του στόματος, ιδίως ένα δισκίο, που περιλαμβάνει τοσυλική σοραφενίμπη πολυμορφικής μορφής III.
CY20231100340T 2012-01-23 2023-07-18 Φαρμακευτικη συνθεση που περιεχει κρυσταλλικη τοσυλικη σοραφενιμπη CY1126099T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261589518P 2012-01-23 2012-01-23
EP12152165 2012-01-23
EP13700919.7A EP2806860B1 (en) 2012-01-23 2013-01-23 Pharmaceutical composition containing crystalline sorafenib tosylate
PCT/EP2013/051219 WO2013110644A1 (en) 2012-01-23 2013-01-23 Pharmaceutical composition containing crystalline sorafenib tosylate

Publications (1)

Publication Number Publication Date
CY1126099T1 true CY1126099T1 (el) 2023-11-15

Family

ID=48872897

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20231100340T CY1126099T1 (el) 2012-01-23 2023-07-18 Φαρμακευτικη συνθεση που περιεχει κρυσταλλικη τοσυλικη σοραφενιμπη

Country Status (7)

Country Link
US (1) US9227938B2 (el)
EP (1) EP2806860B1 (el)
CY (1) CY1126099T1 (el)
ES (1) ES2949817T3 (el)
IN (1) IN2014KN01490A (el)
PL (1) PL2806860T3 (el)
WO (1) WO2013110644A1 (el)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103656656A (zh) * 2013-12-18 2014-03-26 北京科源创欣科技有限公司 甲苯磺酸索拉非尼药物组合物及制备方法
RU2747525C2 (ru) * 2019-11-06 2021-05-06 Общество с ограниченной ответственностью "АМЕДАРТ" Фармацевтический препарат в форме таблетки и способ его получения

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042012A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
KR20090018224A (ko) 2004-09-29 2009-02-19 바이엘 헬스케어 아게 열역학적으로 안정한 형태의 ｂａｙ 43-9006 토실레이트
CN104688697A (zh) 2005-03-07 2015-06-10 拜尔健康护理有限责任公司 用于治疗癌症的包含ω-羧芳基取代的二苯基脲的药物组合物
JP2009543797A (ja) * 2006-07-10 2009-12-10 エラン ファーマ インターナショナル，リミティド ナノ粒子ソラフェニブ製剤
EP2231612A1 (en) 2008-01-17 2010-09-29 Sicor, Inc. Polymorph form iii of sorafenib tosylate, sorafenib tosylate methanol solvate and sorafenib tosylate ethanol solvate, and processes for preparation thereof
WO2010079498A2 (en) * 2009-01-12 2010-07-15 Hetero Research Foundation Novel polymorph of sorafenib tosylate
EP2559431A1 (en) 2011-08-17 2013-02-20 Ratiopharm GmbH Pharmaceutical composition comprising 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide

Also Published As

Publication number Publication date
ES2949817T3 (es) 2023-10-03
EP2806860B1 (en) 2023-04-19
US9227938B2 (en) 2016-01-05
WO2013110644A1 (en) 2013-08-01
US20150080435A1 (en) 2015-03-19
EP2806860A1 (en) 2014-12-03
IN2014KN01490A (el) 2015-10-23
PL2806860T3 (pl) 2023-09-11

Similar Documents

Publication Publication Date Title
DK3181122T3 (da) Farmaceutisk dasatinib-sammensætning
IL246377A0 (en) Pharmaceutical preparations for oral administration
IL230218A (en) Converted atherothecyclic compounds, their preparations and their pharmaceutical preparations
IL237839A0 (en) History of hydropyrrolopyrrole, their preparation and pharmaceutical preparations containing them
EP2982367A4 (en) PHARMACEUTICAL COMPOSITION FOR PARENTERAL ADMINISTRATION CONTAINING DONEPEZIL
IL235414A (en) The history of pyrolotriazinone, their preparation and their pharmaceutical preparations
BR112015004936A2 (pt) composição farmacêutica revestida contendo regorafenib
EP2702054A4 (en) NOVEL BISAMINOQUINOLINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS PREPARED THEREFROM, AND USE THEREOF
TR201821285T4 (tr) CCR3 antagonisti içeren farmasötik formülasyonlar.
UA111717C2 (uk) Склад для перорального введення і ліпофільні солі метилналтрексону
DK3043778T3 (da) Farmaceutiske sammensætninger, der indeholder refametinib
CY1126099T1 (el) Φαρμακευτικη συνθεση που περιεχει κρυσταλλικη τοσυλικη σοραφενιμπη
BR112014009889A2 (pt) compostos dissubstituídos, compostos e composição farmacêutica
DK2815752T3 (da) Oral farmaceutisk sammensætning
DK2542224T3 (da) Oral farmaceutisk sammensætning indeholdende dabigatranetexilat
HK1199822A1 (zh) 口服給藥用醫藥組合物
GEP201706760B (en) Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same
DK3041476T3 (da) Corticosteroid, der indeholder oralt disintegrerende tabletsammensætninger til eosinofil øsofagit
IL246298A0 (en) History of piperidine, their preparation and pharmaceutical preparations containing them
BR112015003116A2 (pt) preparação farmacêutica sólida contendo levotiroxina
SMT201600419B (it) Composizione farmaceutica contenente fosfolipidi
IT1399492B1 (it) Composizioni farmaceutiche effervescenti contenenti n-acetilcisteina.
IL243012A0 (en) History of hydroxy-ethylene, their preparation and pharmaceutical preparations containing them
IL238826A0 (en) History of imidazole - piperidinyl, their preparation and pharmaceutical preparations containing them
ZA201604100B (en) Gastro-retentive oral pharmaceutical compositions